<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Cibinetide</id>
	<title>Cibinetide - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Cibinetide"/>
	<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Cibinetide&amp;action=history"/>
	<updated>2026-04-25T00:39:12Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.org/index.php?title=Cibinetide&amp;diff=6427738&amp;oldid=prev</id>
		<title>Prab: CSV import</title>
		<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Cibinetide&amp;diff=6427738&amp;oldid=prev"/>
		<updated>2025-03-05T06:12:47Z</updated>

		<summary type="html">&lt;p&gt;CSV import&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;{{Short description|Synthetic peptide with potential therapeutic applications}}&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Cibinetide&amp;#039;&amp;#039;&amp;#039; is a synthetic peptide that has been developed for its potential therapeutic effects, particularly in the treatment of [[anemia]] and [[neuropathy]]. It is a derivative of [[erythropoietin]] (EPO), a hormone that is primarily known for its role in [[erythropoiesis]], the production of [[red blood cells]]. Unlike erythropoietin, cibinetide does not stimulate erythropoiesis but retains the tissue-protective effects of EPO.&lt;br /&gt;
&lt;br /&gt;
==Structure and Mechanism of Action==&lt;br /&gt;
[[File:Cibinetide.svg|Cibinetide structure|thumb|right]]&lt;br /&gt;
Cibinetide is a small peptide that mimics the tissue-protective properties of erythropoietin without affecting red blood cell production. It is designed to interact with the [[innate repair receptor]] (IRR), a receptor complex that includes the β common receptor (βcR) and the erythropoietin receptor (EPOR). This interaction is believed to mediate the anti-inflammatory and cytoprotective effects of cibinetide.&lt;br /&gt;
&lt;br /&gt;
The peptide is composed of 11 amino acids, which allows it to bind specifically to the IRR. This binding initiates a cascade of intracellular signaling pathways that lead to reduced inflammation and protection of tissues from damage.&lt;br /&gt;
&lt;br /&gt;
==Therapeutic Applications==&lt;br /&gt;
Cibinetide has been investigated for its potential use in several medical conditions:&lt;br /&gt;
&lt;br /&gt;
===Anemia===&lt;br /&gt;
Although cibinetide does not stimulate erythropoiesis, it has been studied for its ability to alleviate symptoms of anemia by protecting tissues from damage and reducing inflammation. This makes it a potential therapeutic option for patients who cannot tolerate traditional erythropoiesis-stimulating agents.&lt;br /&gt;
&lt;br /&gt;
===Neuropathy===&lt;br /&gt;
Cibinetide has shown promise in the treatment of [[diabetic neuropathy]] and other forms of [[peripheral neuropathy]]. Its ability to reduce inflammation and protect nerve cells from damage makes it a candidate for alleviating the symptoms of neuropathy, such as pain and numbness.&lt;br /&gt;
&lt;br /&gt;
===Other Conditions===&lt;br /&gt;
Research is ongoing to explore the use of cibinetide in other conditions characterized by inflammation and tissue damage, such as [[ischemia-reperfusion injury]] and [[chronic kidney disease]].&lt;br /&gt;
&lt;br /&gt;
==Development and Clinical Trials==&lt;br /&gt;
Cibinetide has undergone various stages of clinical trials to assess its safety and efficacy. These trials have focused on its use in treating conditions like diabetic neuropathy and anemia associated with chronic kidney disease. The results have been promising, showing that cibinetide is well-tolerated and effective in reducing symptoms.&lt;br /&gt;
&lt;br /&gt;
==Related pages==&lt;br /&gt;
* [[Erythropoietin]]&lt;br /&gt;
* [[Anemia]]&lt;br /&gt;
* [[Neuropathy]]&lt;br /&gt;
* [[Ischemia-reperfusion injury]]&lt;br /&gt;
&lt;br /&gt;
[[Category:Peptides]]&lt;br /&gt;
[[Category:Experimental drugs]]&lt;br /&gt;
[[Category:Neuroprotective agents]]&lt;/div&gt;</summary>
		<author><name>Prab</name></author>
	</entry>
</feed>